SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Vor Bio Completes Enrollment in Phase 3 Myasthenia Gravis Trial

Vor Bio reported third-quarter 2026 financial results and said it completed enrollment in the Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis.

VOR

Story updates

12:01:54 PM UTC
SquawkNews
Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3 registrational UPSTREAM oMG trial; first patient dosing anticipated in 1H27Enrollmen…
12:02:29 PM UTC
SquawkNews
Vor Bio reported Q3 2026 results and said it ended the quarter with $481.6M in cash and investments, projecting runway into early 2029. UPSTREAM MG Phase 3 is fully enrolled; topline results remain on track for 1H27.Material DetailsContext by AI AnalystThis update advances a known pivot to immunolo…

Related stories